Avalon Announces Expiration of the Sanofi-Aventis Agreement
News Dec 22, 2005
Avalon Pharmaceuticals, Inc. has announced the expiration of its agreement with sanofi-aventis. The agreement in December 2003 established a collaboration to utilize molecular cytogenetics to identify and validate oncology targets.
The agreement expired as a result of sanofi- aventis' decision not to advance targets that were a focus of the collaboration for further validation.
"We have appreciated the close collaboration with sanofi-aventis on this program," said Paul Young, Ph.D., Vice President of Research for Avalon.
"While they did not select any targets from this program, we expect to continue validation studies on several of the genes as potential Avalon drug discovery targets."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.